These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9420029)

  • 1. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120.
    De Vreese K; Van Nerum I; Vermeire K; Anné J; De Clercq E
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2616-20. PubMed ID: 9420029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.
    de Vreese K; Kofler-Mongold V; Leutgeb C; Weber V; Vermeire K; Schacht S; Anné J; de Clercq E; Datema R; Werner G
    J Virol; 1996 Feb; 70(2):689-96. PubMed ID: 8551604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.
    De Vreese K; Reymen D; Griffin P; Steinkasserer A; Werner G; Bridger GJ; Esté J; James W; Henson GW; Desmyter J; Anné J; De Clercq I
    Antiviral Res; 1996 Mar; 29(2-3):209-19. PubMed ID: 8739600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
    Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
    J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.
    Esté JA; De Vreese K; Witvrouw M; Schmit JC; Vandamme AM; Anné J; Desmyter J; Henson GW; Bridger G; De Clercq E
    Antiviral Res; 1996 Mar; 29(2-3):297-307. PubMed ID: 8739608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.
    Este JA; Schols D; De Vreese K; Van Laethem K; Vandamme AM; Desmyter J; De Clercq E
    Mol Pharmacol; 1997 Jul; 52(1):98-104. PubMed ID: 9224818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the functional relationship between V3 loop and gp120 context with regard to human immunodeficiency virus coreceptor usage using naturally selected sequences and different viral backbones.
    Bagnarelli P; Fiorelli L; Vecchi M; Monachetti A; Menzo S; Clementi M
    Virology; 2003 Mar; 307(2):328-40. PubMed ID: 12667802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.
    De Clercq E; Yamamoto N; Pauwels R; Balzarini J; Witvrouw M; De Vreese K; Debyser Z; Rosenwirth B; Peichl P; Datema R
    Antimicrob Agents Chemother; 1994 Apr; 38(4):668-74. PubMed ID: 7913308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.
    Stamatatos L; Cheng-Mayer C
    J Virol; 1993 Sep; 67(9):5635-9. PubMed ID: 8350416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins.
    Balzarini J; Van Laethem K; Hatse S; Vermeire K; De Clercq E; Peumans W; Van Damme E; Vandamme AM; Bölmstedt A; Schols D
    J Virol; 2004 Oct; 78(19):10617-27. PubMed ID: 15367629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
    Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke TR; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
    Mol Pharmacol; 2000 Sep; 58(3):641-8. PubMed ID: 10953059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
    Platt EJ; Kuhmann SE; Rose PP; Kabat D
    J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.
    Hoffman NG; Seillier-Moiseiwitsch F; Ahn J; Walker JM; Swanstrom R
    J Virol; 2002 Apr; 76(8):3852-64. PubMed ID: 11907225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.
    Schols D; Esté JA; Cabrera C; De Clercq E
    J Virol; 1998 May; 72(5):4032-7. PubMed ID: 9557691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.